These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 37331333

  • 1. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
    Fei S, Lu Y, Chen J, Qi J, Wu W, Wang B, Han Y, Wang K, Han X, Zhou H, Wang J, Chen J.
    Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of immune-checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta-analysis.
    Kundel Y, Sternschuss M, Moore A, Perl G, Brenner B, Goldvaser H.
    Cancer Med; 2020 Oct; 9(20):7613-7625. PubMed ID: 32869544
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
    Sun YT, Lu SX, Lai MY, Yang X, Guan WL, Yang LQ, Li YH, Wang FH, Yang DJ, Qiu MZ.
    Cancer Immunol Immunother; 2024 Jun 04; 73(8):144. PubMed ID: 38832979
    [Abstract] [Full Text] [Related]

  • 4. PD-1/PD-L1 Inhibitors in Combination With Chemo or as Monotherapy vs. Chemotherapy Alone in Advanced, Unresectable HER2-Negative Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Meta-Analysis.
    Beshr MS, Beshr IA, Al Hayek M, Alfaqaih SM, Abuajamieh M, Basheer E, Wali AK, Ekreer M, Chenfouh I, Khashan A, Hassan ET, Elnaami SM, Elhadi M.
    Clin Oncol (R Coll Radiol); 2024 Sep 21. PubMed ID: 39384455
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of anti-PD-1/PD-L1 agents vs chemotherapy in patients with gastric or gastroesophageal junction cancer: a systematic review and meta-analysis.
    Wang BC, Zhang ZJ, Fu C, Wang C.
    Medicine (Baltimore); 2019 Nov 21; 98(47):e18054. PubMed ID: 31764833
    [Abstract] [Full Text] [Related]

  • 6. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
    Yoon HH, Jin Z, Kour O, Kankeu Fonkoua LA, Shitara K, Gibson MK, Prokop LJ, Moehler M, Kang YK, Shi Q, Ajani JA.
    JAMA Oncol; 2022 Oct 01; 8(10):1456-1465. PubMed ID: 36006624
    [Abstract] [Full Text] [Related]

  • 7. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
    Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, Smyth EC, Soon YY, Sundar R.
    J Clin Oncol; 2022 Feb 01; 40(4):392-402. PubMed ID: 34860570
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis.
    Liu BW, Shang QX, Yang YS, Chen LQ.
    Front Oncol; 2023 Feb 01; 13():1077675. PubMed ID: 37114136
    [Abstract] [Full Text] [Related]

  • 9. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
    Moehler M, Högner A, Wagner AD, Obermannova R, Alsina M, Thuss-Patience P, van Laarhoven H, Smyth E.
    Eur J Cancer; 2022 Nov 01; 176():13-29. PubMed ID: 36183651
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reconstruction of unreported subgroup survival data with PD-L1-low expression in advanced/metastatic triple-negative breast cancer using innovative KMSubtraction workflow.
    Li Y, Liang X, Li H, Chen X.
    J Immunother Cancer; 2024 Jan 11; 12(1):. PubMed ID: 38212119
    [Abstract] [Full Text] [Related]

  • 12. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
    Lu Y, Wang W, Wang F.
    Front Immunol; 2023 Jan 11; 14():1171671. PubMed ID: 37205107
    [Abstract] [Full Text] [Related]

  • 13. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
    Noori M, Mahjoubfar A, Azizi S, Fayyaz F, Rezaei N.
    Int Immunopharmacol; 2022 Dec 11; 113(Pt A):109317. PubMed ID: 36252494
    [Abstract] [Full Text] [Related]

  • 14. Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
    Gao X, Ji K, Jia Y, Shan F, Chen Y, Xu N, Jia Z, Liu T, Yang N, Zhong H, Li C, Guo Z, Fan Q, Lin X, Zhang Y, Ren H, Yang H, Yao Z, Liu W, Wang ZM, Li B, Xia M, Shen L, Li Z, Ji J.
    Nat Med; 2024 Jul 11; 30(7):1943-1951. PubMed ID: 38778212
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups.
    Yap DWT, Leone AG, Wong NZH, Zhao JJ, Tey JCS, Sundar R, Pietrantonio F.
    JAMA Oncol; 2023 Feb 01; 9(2):215-224. PubMed ID: 36480211
    [Abstract] [Full Text] [Related]

  • 16. Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
    Xie T, Zhang Z, Zhang X, Qi C, Shen L, Peng Z.
    Front Oncol; 2021 Feb 01; 11():646355. PubMed ID: 34540656
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The efficacy and safety of first‑line anti‑PD‑1/PD‑L1 immunotherapy for gastric esophageal cancer: A systematic review and meta‑analysis of phase III randomized controlled trials.
    Duan X, Du H, Qi R, Yuan M, Shi J.
    Exp Ther Med; 2023 May 01; 25(5):216. PubMed ID: 37123204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.